% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Bacioglu:138738,
author = {Bacioglu, Mehtap and Maia, Luis F and Preische, Oliver and
Schelle, Juliane and Apel, Anja and Kaeser, Stephan A and
Schweighauser, Manuel and Eninger, Timo and Lambert, Marius
and Pilotto, Andrea and Shimshek, Derya R and Neumann, Ulf
and Kahle, Philipp J and Staufenbiel, Matthias and Neumann,
Manuela and Maetzler, Walter and Kuhle, Jens and Jucker,
Mathias},
title = {{N}eurofilament {L}ight {C}hain in {B}lood and {CSF} as
{M}arker of {D}isease {P}rogression in {M}ouse {M}odels and
in {N}eurodegenerative {D}iseases.},
journal = {Neuron},
volume = {91},
number = {1},
issn = {0896-6273},
address = {New York, NY},
publisher = {Elsevier},
reportid = {DZNE-2020-05060},
pages = {56-66},
year = {2016},
abstract = {A majority of current disease-modifying
therapeutic approaches for age-related neurodegenerative
diseases target their characteristic proteopathic lesions
(α-synuclein, Tau, Aβ). To monitor such treatments, fluid
biomarkers reflecting the underlying disease process are
crucial. We found robust increases of neurofilament light
chain (NfL) in CSF and blood in murine models of
α-synucleinopathies, tauopathy, and β-amyloidosis. Blood
and CSF NfL levels were strongly correlated, and NfL
increases coincided with the onset and progression of the
corresponding proteopathic lesions in brain. Experimental
induction of α-synuclein lesions increased CSF and blood
NfL levels, while blocking Aβ lesions attenuated the NfL
increase. Consistently, we also found NfL increases in CSF
and blood of human α-synucleinopathies, tauopathies, and
Alzheimer's disease. Our results suggest that CSF and
particularly blood NfL can serve as a reliable and easily
accessible biomarker to monitor disease progression and
treatment response in mouse models and potentially in human
proteopathic neurodegenerative diseases.},
keywords = {Animals / Axons: metabolism / Biomarkers: blood /
Biomarkers: cerebrospinal fluid / Brain: metabolism / Brain:
pathology / Disease Progression / Intermediate Filaments:
metabolism / Mice, Inbred C57BL / Mice, Transgenic /
Neurodegenerative Diseases: diagnosis / Neurodegenerative
Diseases: metabolism / Neurodegenerative Diseases: pathology
/ Neurofilament Proteins: blood / Neurofilament Proteins:
cerebrospinal fluid / alpha-Synuclein: metabolism /
Biomarkers (NLM Chemicals) / Neurofilament Proteins (NLM
Chemicals) / alpha-Synuclein (NLM Chemicals)},
cin = {AG Jucker / AG Kahle / Ext UKT-Trend / AG Neumann / AG
Maetzler},
ddc = {610},
cid = {I:(DE-2719)1210001 / I:(DE-2719)1210000-4 /
I:(DE-2719)5000056 / I:(DE-2719)1210003 /
I:(DE-2719)5000024},
pnm = {342 - Disease Mechanisms and Model Systems (POF3-342) / 345
- Population Studies and Genetics (POF3-345) / 344 -
Clinical and Health Care Research (POF3-344)},
pid = {G:(DE-HGF)POF3-342 / G:(DE-HGF)POF3-345 /
G:(DE-HGF)POF3-344},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:27292537},
doi = {10.1016/j.neuron.2016.05.018},
url = {https://pub.dzne.de/record/138738},
}